Skip to Content

436 Results Found

  • Article
  • Open Access
11 Citations
5,914 Views
23 Pages

17 February 2020

The life cycles of retroviruses rely on the limited proteolysis catalyzed by the viral protease. Numerous eukaryotic organisms also express endogenously such proteases, which originate from retrotransposons or retroviruses, including DNA damage-induc...

(This article belongs to the Special Issue Biocatalysis: Mechanisms of Proteolytic Enzymes)
  • Review
  • Open Access
8 Citations
3,067 Views
12 Pages

Donor and Donation Images (DDI)—A Scoping Review of What We Know and What We Don’t

  • Nora M. Laskowski,
  • Gerrit Brandt,
  • Katharina Tigges-Limmer,
  • Georg Halbeisen and
  • Georgios Paslakis

26 January 2023

Organ transplantation is associated with significant physical and psychological burden for the recipients. Qualitative reports indicate that organ recipients develop donor and donation images (DDI)—conceptions of the donor and/or the organ. A d...

(This article belongs to the Section Clinical Guidelines)
  • Article
  • Open Access
5 Citations
2,317 Views
14 Pages

The Effects of DDI1 on Inducing Differentiation in Ovine Preadipocytes via Oar-miR-432

  • Meilin Jin,
  • Zehu Yuan,
  • Taotao Li,
  • Huihua Wang and
  • Caihong Wei

Reducing fat deposition in sheep (Ovis aries) tails is one of the most important ways to combat rising costs and control consumer preference. Our previous studies have shown that oar-miR-432 is differentially expressed in the tail adipose tissue...

(This article belongs to the Special Issue Advances in the Understanding of Adipose Tissue Biology and Energy Metabolism)
  • Article
  • Open Access
11 Citations
5,275 Views
19 Pages

Artemisinin Binds and Inhibits the Activity of Plasmodium falciparum Ddi1, a Retroviral Aspartyl Protease

  • Noah Machuki Onchieku,
  • Sonam Kumari,
  • Rajan Pandey,
  • Vaibhav Sharma and ,
  • Mohit Kumar,
  • Arunaditya Deshmukh,
  • Inderjeet Kaur,
  • Asif Mohmmed,
  • Dinesh Gupta and
  • Pawan Malhotra
  • + 7 authors+ 2 authors

11 November 2021

Reduced sensitivity of the human malaria parasite, Plasmodium falciparum, to Artemisinin and its derivatives (ARTs) threatens the global efforts towards eliminating malaria. ARTs have been shown to cause ubiquitous cellular and genetic insults, which...

(This article belongs to the Collection Feature Papers on Parasitic Pathogens)
  • Review
  • Open Access
4 Citations
3,472 Views
15 Pages

Domains in Action: Understanding Ddi1’s Diverse Functions in the Ubiquitin-Proteasome System

  • Artur Fabijan,
  • Bartosz Polis,
  • Agnieszka Zawadzka-Fabijan,
  • Izabela Korabiewska and ,
  • Krzysztof Zakrzewski,
  • Emilia Nowosławska and
  • Michał Chojnacki
  • + 2 authors+ 0 author

The ubiquitin-proteasome system (UPS) is a pivotal cellular mechanism responsible for the selective degradation of proteins, playing an essential role in proteostasis, protein quality control, and regulating various cellular processes, with ubiquitin...

(This article belongs to the Section Biochemistry)
  • Article
  • Open Access
35 Citations
7,049 Views
14 Pages

Proteasome inhibition is used therapeutically to induce proteotoxic stress and trigger apoptosis in cancer cells that are highly dependent on the proteasome. As a mechanism of resistance, inhibition of the cellular proteasome induces the synthesis of...

(This article belongs to the Special Issue Transcriptional Regulation: Molecules, Involved Mechanisms and Misregulation 2019)
  • Article
  • Open Access
15 Citations
3,556 Views
18 Pages

PTB-DDI: An Accurate and Simple Framework for Drug–Drug Interaction Prediction Based on Pre-Trained Tokenizer and BiLSTM Model

  • Jiayue Qiu,
  • Xiao Yan,
  • Yanan Tian,
  • Qin Li and ,
  • Xiaomeng Liu,
  • Yuwei Yang,
  • Henry H. Y. Tong and
  • Huanxiang Liu
  • + 3 authors+ 0 author

23 October 2024

The simultaneous use of two or more drugs in clinical treatment may raise the risk of a drug–drug interaction (DDI). DDI prediction is very important to avoid adverse drug events in combination therapy. Recently, deep learning methods have been...

(This article belongs to the Section Molecular Informatics)
  • Article
  • Open Access
1 Citations
3,927 Views
14 Pages

Adaptation and Implementation of the Dysphagia and Dysphonia Inventory (HSS-DDI) in Greek Patients After Anterior Surgical Removal of the Herniated Cervical Spine

  • Soultana Papadopoulou,
  • Aliki I. Venetsanopoulou,
  • Avraam Ploumis,
  • Kalliopi Megari and ,
  • Evaggelia-Maria Perivolioti,
  • Nikoleta Tsipa,
  • Andreas Zygouris and
  • Spyridon Voulgaris
  • + 3 authors+ 0 author

Background: Anterior cervical discectomy and fusion (ACDF) is a widely performed surgical intervention for cervical spine herniation (CSH) to alleviate symptoms such as pain, weakness, and restricted mobility. Despite its efficacy, ACDF is associated...

(This article belongs to the Special Issue Clinical Diagnosis of Otorhinolaryngology)
  • Article
  • Open Access
366 Views
19 Pages

29 September 2026

STS316L seamless high-pressure cylinders are used for high-purity specialty gases, motivating efficient manufacture by deep drawing and ironing (D.D.I.). This study presents a six-to-four stage integration that combines baseline Stages 2–3 and...

(This article belongs to the Section Mechanical Engineering)
  • Article
  • Open Access
25 Citations
5,230 Views
7 Pages

In Silico Prediction of Drug–Drug Interactions Mediated by Cytochrome P450 Isoforms

  • Alexander V. Dmitriev,
  • Anastassia V. Rudik,
  • Dmitry A. Karasev,
  • Pavel V. Pogodin and ,
  • Alexey A. Lagunin,
  • Dmitry A. Filimonov and
  • Vladimir V. Poroikov
  • + 2 authors+ 0 author

Drug–drug interactions (DDIs) can cause drug toxicities, reduced pharmacological effects, and adverse drug reactions. Studies aiming to determine the possible DDIs for an investigational drug are part of the drug discovery and development process and...

(This article belongs to the Special Issue Drug–Drug Interactions)
  • Article
  • Open Access
6 Citations
4,292 Views
17 Pages

16 December 2022

Ensuring safe and comfortable conditions for pedestrians necessitates specific strategies at intersections and service interchanges where traffic and pedestrians interact in complex ways with other modes of transportation. This study aims to investig...

(This article belongs to the Special Issue Evaluation of Sustainable Transportation Infrastructure)
  • Article
  • Open Access
1 Citations
1,409 Views
36 Pages

Drug–drug interaction (DDI) prediction plays a critical role in optimizing therapeutic outcomes and enhancing patient safety. DDIs pose challenges in drug discovery, often leading to adverse effects, reduced efficacy, or unexpected outcomes. AI...

(This article belongs to the Special Issue Advancements in Healthcare Data Science: Innovations, Challenges and Applications)
  • Article
  • Open Access
6 Citations
8,534 Views
19 Pages

Evaluation of Drug Interactions in Hospitalized Patients with Respiratory Disorders in Greece

  • Marios Spanakis,
  • Petros Ioannou,
  • Sotiris Tzalis,
  • Flora Chouzouri and ,
  • Evridiki Patelarou,
  • Diamantis P. Kofteridis,
  • Katerina M. Antoniou,
  • Sophia E. Schiza,
  • Athina Patelarou and
  • Nikos Tzanakis
  • + 5 authors+ 0 author

5 February 2023

Background: Patients with respiratory disorders often have additional diseases and are usually treated with more than one medication to manage their respiratory conditions as well as additional comorbidities. Thus, they are frequently exposed to poly...

  • Article
  • Open Access
22 Citations
4,672 Views
7 Pages

Prediction of Severity of Drug-Drug Interactions Caused by Enzyme Inhibition and Activation

  • Alexander Dmitriev,
  • Dmitry Filimonov,
  • Alexey Lagunin,
  • Dmitry Karasev and ,
  • Pavel Pogodin,
  • Anastasiya Rudik and
  • Vladimir Poroikov
  • + 2 authors+ 0 author

31 October 2019

Drug-drug interactions (DDIs) severity assessment is a crucial problem because polypharmacy is increasingly common in modern medical practice. Many DDIs are caused by alterations of the plasma concentrations of one drug due to another drug inhibiting...

(This article belongs to the Special Issue Recent Trends on Enzymes Inhibitors and Activators in Drug Research II)
  • Article
  • Open Access
572 Views
24 Pages

Background: Drug–drug interactions (DDIs) account for about 30% of adverse drug reactions and 5–10% of hospital deaths. Combination therapy increases DDI risks, yet extracting DDIs from biomedical text remains challenging: existing method...

(This article belongs to the Section Drug Discovery, Development and Delivery)
  • Review
  • Open Access
26 Citations
9,231 Views
18 Pages

Current Knowledge about Providing Drug–Drug Interaction Services for Patients—A Scoping Review

  • Tora Hammar,
  • Sara Hamqvist,
  • My Zetterholm,
  • Päivi Jokela and
  • Mexhid Ferati

Drug–drug interactions (DDIs) pose a major problem to patient safety. eHealth solutions have the potential to address this problem and generally improve medication management by providing digital services for health care professionals and patients. C...

(This article belongs to the Special Issue Digital Solutions to Improve Medication Management)
  • Review
  • Open Access
9 Citations
3,229 Views
12 Pages

Innovative Approaches to Optimize Clinical Transporter Drug–Drug Interaction Studies

  • Sabina Paglialunga,
  • Natacha Benrimoh and
  • Aernout van Haarst

Of the 450 cell membrane transporters responsible for shuttling substrates, nutrients, hormones, neurotransmitters, antioxidants, and signaling molecules, approximately nine are associated with clinically relevant drug–drug interactions (DDIs)...

(This article belongs to the Special Issue New Insights into Transporters in Drug Development)
  • Article
  • Open Access
26 Citations
9,698 Views
19 Pages

A Mechanistic, Enantioselective, Physiologically Based Pharmacokinetic Model of Verapamil and Norverapamil, Built and Evaluated for Drug–Drug Interaction Studies

  • Nina Hanke,
  • Denise Türk,
  • Dominik Selzer,
  • Sabrina Wiebe and ,
  • Éric Fernandez,
  • Peter Stopfer,
  • Valerie Nock and
  • Thorsten Lehr
  • + 3 authors+ 0 author

The calcium channel blocker and antiarrhythmic agent verapamil is recommended by the FDA for drug–drug interaction (DDI) studies as a moderate clinical CYP3A4 index inhibitor and as a clinical Pgp inhibitor. The purpose of the presented work wa...

(This article belongs to the Special Issue Applications of Physiologically-Based Pharmacokinetic (PBPK) Modeling)
  • Article
  • Open Access
600 Views
11 Pages

Introducing a Sustainable Framework for Preschool Visual Acuity Screening: The Alexandroupolis Case

  • Georgios Labiris,
  • Christos Giazitzis,
  • Christina Mitsi,
  • Minas Bakirtzis and ,
  • Eirini-Kanella Panagiotopoulou,
  • Eirini Vavanou,
  • Aristeidis Konstantinidis,
  • Panagiota Ntonti and
  • Nikolaos Polyzos
  • + 4 authors+ 0 author

3 March 2026

Background/Objectives: Western societies introduce school-based or school-linked programs in order to improve the physical health status of students and prevent the negative impact of the late diagnosis of a series of diseases and conditions. Prescho...

(This article belongs to the Special Issue Progress in Clinical Diagnosis and Therapy in Ophthalmology)
  • Review
  • Open Access
52 Citations
13,485 Views
17 Pages

Pharmacokinetic and Pharmacodynamic Drug–Drug Interactions: Research Methods and Applications

  • Lei Sun,
  • Kun Mi,
  • Yixuan Hou,
  • Tianyi Hui and ,
  • Lan Zhang,
  • Yanfei Tao,
  • Zhenli Liu and
  • Lingli Huang
  • + 3 authors+ 0 author

Because of the high research and development cost of new drugs, the long development process of new drugs, and the high failure rate at later stages, combining past drugs has gradually become a more economical and attractive alternative. However, the...

(This article belongs to the Special Issue Pharmacology and Toxicology Metabolism of Synthetic and Natural Compounds)
  • Article
  • Open Access
2 Citations
2,764 Views
16 Pages

Background: Accurate assessment of CYP2C induction-mediated drug–drug interactions (DDIs) remains a challenge, despite the importance of CYP2C enzymes in drug metabolism. Limitations in available models and scarce clinical induction data have h...

(This article belongs to the Special Issue Development of Physiologically Based Pharmacokinetic (PBPK) Modeling)
  • Article
  • Open Access
15 Citations
8,786 Views
19 Pages

Trimethoprim is a frequently-prescribed antibiotic and therefore likely to be co-administered with other medications, but it is also a potent inhibitor of multidrug and toxin extrusion protein (MATE) and a weak inhibitor of cytochrome P450 (CYP) 2C8....

(This article belongs to the Special Issue Applications of Physiologically-Based Pharmacokinetic (PBPK) Modeling)
  • Article
  • Open Access
19 Citations
7,111 Views
19 Pages

A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug–Drug Interaction Modeling

  • Laura Maria Fuhr,
  • Fatima Zahra Marok,
  • Maximilian Mees,
  • Felix Mahfoud and ,
  • Dominik Selzer and
  • Thorsten Lehr
  • + 1 author+ 0 author

The antihypertensive felodipine is a calcium channel blocker of the dihydropyridine type, and its pharmacodynamic effect directly correlates with its plasma concentration. As a sensitive substrate of cytochrome P450 (CYP) 3A4 with high first-pass met...

(This article belongs to the Special Issue Dose-Dependent Pharmacokinetics and Drug Interactions)
  • Article
  • Open Access
69 Citations
13,328 Views
19 Pages

The anticonvulsant carbamazepine is frequently used in the long-term therapy of epilepsy and is a known substrate and inducer of cytochrome P450 (CYP) 3A4 and CYP2B6. Carbamazepine induces the metabolism of various drugs (including its own); on the o...

(This article belongs to the Special Issue Applications of Physiologically-Based Pharmacokinetic (PBPK) Modeling)
  • Article
  • Open Access
17 Citations
4,966 Views
14 Pages

Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors

  • Mario Occhipinti,
  • Marta Brambilla,
  • Giulia Galli,
  • Sara Manglaviti and ,
  • Maristella Giammaruco,
  • Arsela Prelaj,
  • Roberto Ferrara,
  • Alessandro De Toma,
  • Claudia Proto and
  • Paolo Marchetti
  • + 13 authors+ 8 authors

(1) Background. The onset of a drug–drug interaction (DDI) may affect treatment efficacy and toxicity of advanced non-small-cell lung cancer (aNSCLC) patients during epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) use. Here we...

(This article belongs to the Section Pharmacogenetics)
  • Article
  • Open Access
17 Citations
11,824 Views
19 Pages

Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug–Drug Interactions of Phenytoin

  • Leyanis Rodriguez-Vera,
  • Xuefen Yin,
  • Mohammed Almoslem,
  • Karolin Romahn and ,
  • Brian Cicali,
  • Viera Lukacova,
  • Rodrigo Cristofoletti and
  • Stephan Schmidt
  • + 3 authors+ 0 author

Regulatory agencies worldwide expect that clinical pharmacokinetic drug–drug interactions (DDIs) between an investigational new drug and other drugs should be conducted during drug development as part of an adequate assessment of the drug&rsquo...

(This article belongs to the Special Issue Pharmacokinetics and Drug Interactions)
  • Article
  • Open Access
11 Citations
8,335 Views
25 Pages

Applying Physiologically Based Pharmacokinetic Modeling to Interpret Carbamazepine’s Nonlinear Pharmacokinetics and Its Induction Potential on Cytochrome P450 3A4 and Cytochrome P450 2C9 Enzymes

  • Xuefen Yin,
  • Brian Cicali,
  • Leyanis Rodriguez-Vera,
  • Viera Lukacova and ,
  • Rodrigo Cristofoletti and
  • Stephan Schmidt
  • + 1 author+ 0 author

Carbamazepine (CBZ) is commonly prescribed for epilepsy and frequently used in polypharmacy. However, concerns arise regarding its ability to induce the metabolism of other drugs, including itself, potentially leading to the undertreatment of co-admi...

(This article belongs to the Special Issue Advances in Pharmacokinetics and Drug Interactions)
  • Article
  • Open Access
9 Citations
3,022 Views
15 Pages

26 September 2025

Background: Drug–drug interactions (DDIs) involve pharmacokinetic or pharmacodynamic changes that occur when multiple drugs are co-administered, potentially leading to reduced efficacy or adverse effects. As polypharmacy becomes more prevalent,...

(This article belongs to the Section Drug Discovery, Development and Delivery)
  • Article
  • Open Access
18 Citations
15,068 Views
22 Pages

The noradrenaline and dopamine reuptake inhibitor bupropion is metabolized by CYP2B6 and recommended by the FDA as the only sensitive substrate for clinical CYP2B6 drug–drug interaction (DDI) studies. The aim of this study was to build a whole-body p...

(This article belongs to the Special Issue Applications of Physiologically-Based Pharmacokinetic (PBPK) Modeling)
  • Article
  • Open Access
143 Views
18 Pages

Real-World Medication Utilization and Potential Pharmacokinetic Drug–Drug Interaction Liabilities in Patients with Heart Failure and Chronic Kidney Disease

  • Mareena Biju,
  • Annie Carlisle,
  • Ling Zhang,
  • Jennifer Schaible and ,
  • Beshoy Armanios,
  • Xin Chen,
  • Ashish Sharma and
  • Fenglei Huang
  • + 3 authors+ 0 author

Background/Objectives: Patients with heart failure (HF) and chronic kidney disease (CKD) frequently receive complex multidrug regimens, increasing the potential for pharmacokinetic drug–drug interactions (DDIs). Methods: This study used U.S. Op...

(This article belongs to the Special Issue Drug–Drug Interactions—New Perspectives)
  • Article
  • Open Access
3 Citations
3,765 Views
9 Pages

Prevalence of Cannabidiol (CBD) Use Among Patients Taking Medications with Known Drug–Drug Interactions: A Cross-Sectional Analysis

  • Hunter Geneau,
  • Michael Kovasala,
  • Grant Brown,
  • Simeon Holmes and ,
  • Olivia Hime,
  • Michael McNally,
  • Michael McFayden,
  • Kori Brewer and
  • G. Kirk Jones
  • + 4 authors+ 0 author

2 November 2025

Introduction: Cannabidiol (CBD) is widely available over the counter for presumed medical and recreational purposes. Despite its non-psychoactive nature, CBD exhibits intrinsic pharmacological activity that may lead to potential adverse drug events (...

(This article belongs to the Section Pharmacology)
  • Article
  • Open Access
23 Citations
6,444 Views
23 Pages

Transmembrane transport of metformin is highly controlled by transporters including organic cation transporters (OCTs), plasma membrane monoamine transporter (PMAT), and multidrug/toxin extrusions (MATEs). Hepatic OCT1, intestinal OCT3, renal OCT2 on...

(This article belongs to the Special Issue Pharmacokinetics and Drug Interactions)
  • Article
  • Open Access
30 Citations
7,138 Views
19 Pages

Cabozantinib (CAB) is a receptor tyrosine kinase inhibitor approved for the treatment of several cancer types. Enterohepatic recirculation (EHC) of the substance is assumed but has not been further investigated yet. CAB is mainly metabolized via CYP3...

(This article belongs to the Special Issue Pharmacokinetics and Drug Interactions)
  • Article
  • Open Access
18 Citations
4,731 Views
19 Pages

A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug–Drug Interaction Frequently Observed in Graft versus Host Disease Patients

  • Bettina Gerner,
  • Fatemeh Aghai-Trommeschlaeger,
  • Sabrina Kraus,
  • Götz Ulrich Grigoleit and ,
  • Sebastian Zimmermann,
  • Max Kurlbaum,
  • Hartwig Klinker,
  • Nora Isberner and
  • Oliver Scherf-Clavel
  • + 4 authors+ 0 author

Ruxolitinib (RUX) is approved for the treatment of steroid-refractory acute and chronic graft versus host disease (GvHD). It is predominantly metabolized via cytochrome P450 (CYP) 3A4. As patients with GvHD have an increased risk of invasive fungal i...

(This article belongs to the Section Pharmacokinetics and Pharmacodynamics)
  • Article
  • Open Access
18 Citations
9,405 Views
22 Pages

The antiplatelet agent clopidogrel is listed by the FDA as a strong clinical index inhibitor of cytochrome P450 (CYP) 2C8 and weak clinical inhibitor of CYP2B6. Moreover, clopidogrel is a substrate of—among others—CYP2C19 and CYP3A4. This...

(This article belongs to the Special Issue Drug–Drug Interactions (Volume II))
  • Article
  • Open Access
6 Citations
4,789 Views
14 Pages

Background: Morphine is a commonly prescribed opioid analgesic used to treat chronic pain. Morphine undergoes glucuronidation by UDP-glucuronosyltransferase (UGT) 2B7 to form morphine-3-glucuronide and morphine-6-glucuronide. Morphine is the gold sta...

(This article belongs to the Special Issue Pharmacokinetics and Drug–Drug Interactions of Novel Psychotropic Drugs)
  • Article
  • Open Access
5 Citations
4,095 Views
15 Pages

Objective: This study assessed the pharmacokinetic (PK) interactions between clarithromycin (a P-glycoprotein [P-gp] inhibitor) and four direct oral anticoagulants (DOACs) (P-gp substrates) using physiologically based PK (PBPK) models to elucidate th...

(This article belongs to the Section Pharmacokinetics and Pharmacodynamics)
  • Article
  • Open Access
677 Views
18 Pages

Architect’s Role Between Data-Driven and Artificial Intelligence-Enhanced Design

  • Sladjana Markovic,
  • Ana Nikezic and
  • Irina Miodragovic Vella

In contemporary scientific disciplines, there is an increasing interest in adopting artificial intelligence (AI) as a cornerstone of data-driven intelligence (DDI). While DDI has not yet been fully integrated into architectural design, AI has already...

(This article belongs to the Special Issue Architecture in the Digital Age)
  • Article
  • Open Access
6 Citations
3,135 Views
10 Pages

Evaluation of Drug Interactions in Patients Treated with DAAs for Hepatitis C Therapy with Comorbidities and Cardiovascular Issues—A Delphi Consensus Project

  • Claudio Borghi,
  • Alessia Ciancio,
  • Ivan Gentile,
  • Pasquale Perrone Filardi and ,
  • Patrizio Pasqualetti and
  • Stefano Brillanti
  • + 1 author+ 0 author

25 November 2022

Orally administered direct-acting antivirals (DAAs) have dramatically changed the possibility of curing HCV (hepatitis C virus) infection, with the two principal HCV regimens based on the combination of glecaprevir + pibrentasvir (GLE-PIB) and sofosb...

(This article belongs to the Section Infectious Diseases)
  • Article
  • Open Access
10 Citations
6,586 Views
24 Pages

9 October 2022

Antimicrobial therapy is often a life-saving medical intervention for inpatients and outpatients. Almost all medical disciplines are involved in this therapeutic procedure. Knowledge of adverse drug reactions (ADRs) and drug-drug interactions (DDIs)...

(This article belongs to the Special Issue Clinical Pharmacology and Pharmacy of Antimicrobial Agents)
  • Article
  • Open Access
24 Citations
5,504 Views
15 Pages

Examination of the Impact of CYP3A4/5 on Drug–Drug Interaction between Schizandrol A/Schizandrol B and Tacrolimus (FK-506): A Physiologically Based Pharmacokinetic Modeling Approach

  • Qingfeng He,
  • Fengjiao Bu,
  • Qizhen Wang,
  • Min Li and ,
  • Jiaying Lin,
  • Zhijia Tang,
  • Wen Yao Mak,
  • Xiaomei Zhuang,
  • Xiao Zhu and
  • Xiaoqiang Xiang
  • + 6 authors+ 1 author

Schizandrol A (SZA) and schizandrol B (SZB) are two active ingredients of Wuzhi capsule (WZC), a Chinese proprietary medicine commonly prescribed to alleviate tacrolimus (FK-506)-induced hepatoxicity in China. Due to their inhibitory effects on cytoc...

(This article belongs to the Section Molecular Pharmacology)
  • Article
  • Open Access
34 Citations
7,542 Views
17 Pages

Nelfinavir Inhibits the TCF11/Nrf1-Mediated Proteasome Recovery Pathway in Multiple Myeloma

  • Dominika Fassmannová,
  • František Sedlák,
  • Jindřich Sedláček,
  • Ivan Špička and
  • Klára Grantz Šašková

25 April 2020

Proteasome inhibitors are the backbone of multiple myeloma therapy. However, disease progression or early relapse occur due to development of resistance to the therapy. One important cause of resistance to proteasome inhibition is the so-called bounc...

(This article belongs to the Collection Drug Resistance and Novel Therapies in Cancers)
  • Article
  • Open Access
21 Citations
4,345 Views
17 Pages

Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions between Elexacaftor/Tezacaftor/Ivacaftor and Tacrolimus in Lung Transplant Recipients

  • Eunjin Hong,
  • Eugeniu Carmanov,
  • Alan Shi,
  • Peter S. Chung and ,
  • Adupa P. Rao,
  • Kevin Forrester and
  • Paul M. Beringer
  • + 2 authors+ 0 author

Elexacaftor/tezacaftor/ivacaftor (ETI) treatment has potential benefits in lung transplant recipients, including improvements in extrapulmonary manifestations, such as gastrointestinal and sinus disease; however, ivacaftor is an inhibitor of cytochro...

(This article belongs to the Special Issue Model-Informed Drug Discovery and Development, 2nd Edition)
  • Article
  • Open Access
2 Citations
3,598 Views
12 Pages

21 June 2022

An improved protocol for the transformation of ribonucleosides into 2′,3′-dideoxynucleoside and 2′,3′-didehydro-2′,3′-dideoxynucleoside derivatives, including the anti-HIV drugs stavudine (d4T), zalcitabine (ddC) a...

(This article belongs to the Special Issue Frontiers in Nucleic Acid Chemistry—in Memory of Professor Enrique Pedroso for His Outstanding Contributions to Nucleic Acid Chemistry)
  • Review
  • Open Access
2 Citations
2,400 Views
16 Pages

Hepatitis C Direct-Acting Antivirals in the Immunosuppressed Host: Mechanisms, Interactions, and Clinical Outcomes

  • Hoor AlKaabi,
  • Siham AlSinani,
  • Mohamed El-Kassas,
  • Khalid A. Alswat and
  • Khalid M. AlNaamani

26 October 2025

Direct-acting antivirals (DAAs) have transformed hepatitis C virus (HCV) management, offering high cure rates, favorable safety, and simplified regimens. Management in immunosuppressed patients remains challenging due to drug–drug interactions...

(This article belongs to the Section Viral Immunology, Vaccines, and Antivirals)
  • Review
  • Open Access
4 Citations
3,246 Views
36 Pages

Medical Marijuana and Treatment Personalization: The Role of Genetics and Epigenetics in Response to THC and CBD

  • Małgorzata Kalak,
  • Anna Brylak-Błaszków,
  • Łukasz Błaszków and
  • Tomasz Kalak

12 December 2025

Personalizing therapy using medical marijuana (MM) is based on understanding the pharmacogenomics (PGx) and drug–drug interactions (DDIs) involved, as well as identifying potential epigenetic risk markers. In this work, the evidence regarding t...

(This article belongs to the Section Epigenomics)
  • Article
  • Open Access
1 Citations
747 Views
24 Pages

Road Drainage Infrastructure Diagnostics and Deficiency Indexing in ENSO-Vulnerable Andean Corridors: A STEM–PjBL Field Assessment

  • Holger Manuel Benavides-Muñoz,
  • Manuel Ignacio Ayala-Chauvin and
  • Leirys María Benavides-Ortega

15 May 2026

Road drainage infrastructure in ENSO-vulnerable Andean regions faces compounding threats from climatic variability, geometric inadequacy, and systemic maintenance neglect. This study presents a STEM-integrated Project-Based Learning (PjBL) diagnostic...

(This article belongs to the Special Issue Resilient Infrastructure for Climate Action: The Nexus of Technology, Management, and Innovation)
  • Article
  • Open Access
572 Views
18 Pages

Computational Prediction of the Severity of Adverse Drug Reactions Caused by Drug–Drug Interactions

  • Vladislav S. Sukhachev,
  • Sergey M. Ivanov,
  • Dmitry A. Filimonov,
  • Anastasia V. Rudik and
  • Vladimir V. Poroikov

24 August 2026

Background/Objectives: Adverse drug reactions (ADRs) caused by drug–drug interactions (DDIs) represent an important problem in pharmacotherapy, especially in patients receiving multiple medications. Most computational approaches to DDI-associat...

(This article belongs to the Special Issue Emerging Computational Approaches in Drug Discovery and Design)
  • Article
  • Open Access
1,502 Views
19 Pages

Evaluation of Dexmedetomidine-Associated Bradycardia and Related Drug–Drug Interactions Using Electronic Health Record (EHR) and miRNA Target Analysis

  • Xinran Zhu,
  • Suguna Aishwarya Kuppa,
  • Robert Morris,
  • Lan Bui and ,
  • Xiaoming Liu,
  • Angela Hill and
  • Feng Cheng
  • + 2 authors+ 0 author

Dexmedetomidine is a commonly used sedative because it has minimal adverse effects on respiratory function. Nevertheless, its cardiovascular safety profile, particularly bradycardia risk and drug–drug interactions (DDIs), remains incompletely u...

(This article belongs to the Section Biochemistry, Molecular and Cellular Biology)
  • Article
  • Open Access
10 Citations
3,381 Views
16 Pages

The Association Between Dexmedetomidine and Bradycardia: An Analysis of FDA Adverse Event Reporting System (FAERS) Data and Transcriptomic Profiles

  • Robert Morris,
  • Suguna Aishwarya Kuppa,
  • Xinran Zhu,
  • Kun Bu and ,
  • Weiru Han and
  • Feng Cheng
  • + 1 author+ 0 author

22 May 2025

Background/Objectives: Bradycardia, an uncharacteristically low heart rate below 60 bpm, is a commonly reported adverse drug event (ADE) in individuals administered dexmedetomidine for sedation. Dexmedetomidine is frequently used as a sedative and an...

(This article belongs to the Section Bioinformatics)

of 9